Connecting Capital with Innovation

The Investment Summit­ — held during BIO Asia–Taiwan 2025 — is the premier destination for global investors, financial institutions, and biotech leaders to explore emerging opportunities within Asia’s thriving life sciences ecosystem. Over two days, the summit features keynote presentations, high-level panel discussions, and curated roadshow appearances from some of the region’s most exciting companies, all seeking strategic funding, licensing, and cross-border partnerships.

Don’t Miss the Region’s Premier Investment-Biotech Convergence

What to Expect

⬛Roadshow Spotlight

Discover investment-ready biotech growth-stage companies and scale-ups pitching groundbreaking solutions in therapeutics, medtech, CDMO, and digital health.

⬛ Panel Discussions

      Day 1 – July 23:

• BD & Licensing Trends
  The session features executives from AbbVie, Gilead Sciences, and Novo Nordisk, who will discuss dealmaking and innovation pipelines. The discussion will be moderated by John Tasi from Syncona.

• Global Investment Trends
  Moderated by Gur Roshwalb, former Partner at aMoon Fund, now with 1E Therapeutics, with panelists from Illumina, VMS Group and more.

     Day 2 – July 24:

• MedTech Panel: The Next Frontier
  Industry voices from Kyoto University Innovation Capital, Cobro Ventures, with panelist from MedTech Trinity LifeSciences.

⬛ Networking Opportunities

• Taipei Night: Investment Networking Reception (July 23, 18:00–20:00)

• BIO Asia–Taiwan Taiwan Night (July 24, 18:30–21:00)

Who Should Attend?

• VC/PE/Institutional Investors in biotech, healthcare, and medtech

• Biopharma executives seeking partners or capital

• Family offices and sovereign funds eyeing Asia-based innovation

• Startups and scale-ups ready to pitch and expand globally